Writing in a Perspectives article, Michele K. Dougherty, PhD, and colleagues at the FDA predict the success of the agency’s biosimilars program and anticipate that as biosimilar development programs continue to mature, there will be an influx of biosimilar approval applications filed at the agency, and that the FDA and the biopharmaceutical industry will continue to build on the lessons learned from early biosimilar development programs.
The FDA has seen a steady increase in biosimilar development programs since the passage of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), with 9 biosimilars approved by the end of 2017 and 68 active biosimilar programs in development. Writing in a Perspectives article published in the January 2018 issue of Clinical Pharmacology & Therapeutics, Michele K. Dougherty, PhD, and colleagues at the FDA predict the success of the agency’s biosimilars program and anticipate that as biosimilar development programs continue to mature, there will be an influx of biosimilar approval applications filed at the agency, and that the FDA and the biopharmaceutical industry will continue to build on the lessons learned from early biosimilar development programs. The authors believe the future will bring greater patient access to safe, effective, and presumably more affordable biological products though the approval of more biosimilar products.
Dougherty and her coauthors explain the history of the US biosimilar approval pathway as laid out by the BPCIA, which requires that a proposed biosimilar product demonstrate, through a stepwise development approach, that is has the same strength, route of administration, and dosage form as the FDA-approved reference biologic, and that it uses the same mechanism of action (MOA) for the proposed conditions of use that the reference product previously showed during its approval process. The authors stress that the BPCIA abbreviated licensing pathway for biosimilars is not a lower approval standard, but rather allows for reliance on the FDA’s previous finding of safety and effectiveness for the reference product, promoting a shorter and less costly development program for biosimilars. Biosimilar sponsors provide extensive data from analytic studies, nonclinical studies, and clinical studies, they note, but “the goal of the biosimilar program is not to re-establish the safety and efficacy of the product but rather to demonstrate that the biologic product is biosimilar to the reference product.”
They explain that the “totality of the data” provides evidence of biosimilarity and why no single study is deemed pivotal in the biosimilar approval process. The totality of data and information submitted in the biologic licensing application (BLA) must support the demonstration of biosimilarity; extrapolation of data for different indications must be scientifically justified, and factors considered that include MOA in each indication sought, they note. Concerns about pharmacokinetics, immunogenicity, and toxicity in different patient populations and uses are addressed in this process. The authors conclude that the biosimilar licensing pathway results in biosimilar products that patients and physicians can rely upon as far as safety and effectiveness in the same way that they would for the reference product in each condition of use for which the biosimilar product is approved.
Finally, Dougherty and colleagues note that the FDA aims to increase transparency in the review process for biosimilars, allowing for enhanced communication during the review cycle to achieve more first-cycle approvals. Labeling for biosimilars is an area the FDA and the industry are addressing through guidance and implementation during licensure of the first biosimilar products, as well as interchangeability with the reference product.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.